Abstracts tagged "certolizumab pegol"

Abstract Number: 102 • 2014 ACR/ARHP Annual Meeting
Real-World Utilization, Patient Characteristics and Persistency of Certolizumab Pegol Vs Other Anti-TNFs for the Treatment of Rheumatoid Arthritis in the United Kingdom
Frances Humby¹, Stephen Kelly¹, Angela V. Bedenbaugh², Nawab Qizilbash^3,4, Jochen Dunkel⁵, Belén SanJose³, Ignacio Mendez³, Jennifer Timoshanko⁶ and Jeyanesh Tambiah², ¹Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom, ²UCB Pharma, Smyrna, GA, ³OXON Epidemiology, London, United Kingdom, ⁴Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom, ⁵UCB Pharma, Monheim, Germany, ⁶UCB Pharma, Slough, United Kingdom
Background/Purpose Several anti-TNFs are currently approved in Europe for RA treatment including certolizumab pegol (CZP), adalimumab (ADA), etanercept (ETN), golimumab and infliximab. UK NICE guidance…
Abstract Number: 433 • 2013 ACR/ARHP Annual Meeting
Retrospective Analysis Of Certolizumab Pegol Use During Pregnancy: Update Of Impact On Birth Outcomes
Megan E. B. Clowse¹, Douglas C. Wolf², Frauke Förger³, John J. Cush⁴, Christian Stach⁵, Gordana Kosutic⁶, Susan Williams⁶, Chidi Maduka⁶ and Uma Mahadevan⁷, ¹Rheumatology, Duke University Medical Center, Durham, NC, ²Atlanta Gastroenterology Associates, Atlanta, GA, ³Department of Rheumatology and Clinical Immunology and Allergology, Inselspital, University of Bern, Bern, Switzerland, ⁴Baylor Research Institute and Baylor University Medical Center, Dallas, TX, ⁵UCB Pharma, Monheim, Germany, ⁶UCB Pharma, Raleigh, NC, ⁷UCSF Medical Center, San Francisco, CA
Background/Purpose: Certolizumab pegol (CZP) is a PEGylated Fc-free anti-TNF approved in 45 countries for the treatment of rheumatoid arthritis (RA) and/or Crohn's disease (CD). An…
Abstract Number: 326 • 2013 ACR/ARHP Annual Meeting
Reduction Of Disease Burden On Workplace and Household Productivity In Psoriatic Arthritis Over 48 Weeks Of Treatment With Certolizumab Pegol
Arthur Kavanaugh¹, Dafna D. Gladman², Désirée M. van der Heijde³, Oana Purcaru⁴ and Philip J. Mease⁵, ¹Division of Rheumatology Allergy and Immunology, University of California San Diego, San Diego, CA, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴UCB Pharma, Brussels, Belgium, ⁵Division of Rheumatology Research, Swedish Medical Center and University of Washington, Seattle, WA
Background/Purpose: Compared to the general population, patients (pts) with psoriatic arthritis (PsA) suffer greater amounts of disability and substantially lower employment rates.1 To date there…
Abstract Number: 2321 • 2013 ACR/ARHP Annual Meeting
Long-Term Safety and Efficacy Of Certolizumab Pegol In Combination With Methotrexate In The Treatment Of Rheumatoid Arthritis: 5-Year Results From a 24-Week Randomized Controlled Trial and Open-Label Extension Study
Josef S. Smolen¹, Ronald van Vollenhoven², Arthur Kavanaugh³, Vibeke Strand⁴, Jiri Vencovsky⁵, Michael H. Schiff⁶, Robert Landewé⁷, Boulos Haraoui⁸, Susan Walker⁹ and Désirée van der Heijde¹⁰, ¹Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ²Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ³Division of Rheumatology Allergy and Immunology, University of California San Diego, San Diego, CA, ⁴Adjunct, Division of Immunology / Rheumatology, Stanford University, Palo Alto, CA, ⁵Institute of Rheumatology, Department of Clinical and Experimental Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ⁶Rheumatology Division, University of Colorado, Denver, CO, ⁷Academic Medical Center Amsterdam & Atrium Medical Center, Heerlen, Netherlands, ⁸Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada, ⁹UCB Pharma, Raleigh, NC, ¹⁰Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: In the RAPID2 randomized controlled trial (RCT; NCT00160602), certolizumab pegol (CZP) +MTX every 2 weeks (Q2W) improved signs and symptoms of rheumatoid arthritis (RA)…
Abstract Number: 1520 • 2013 ACR/ARHP Annual Meeting
Reduction Of Disease Burden On Workplace and Household Productivity In Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis, Over 48 Weeks Of Treatment With Certolizumab Pegol
Désirée M. van der Heijde¹, Jürgen Braun², Martin Rudwaleit³, Oana Purcaru⁴ and Arthur Kavanaugh⁵, ¹Dept of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumazentrum Ruhrgebiet, Herne, Germany, ³Endokrinologikum, Berlin, Germany, ⁴UCB Pharma, Brussels, Belgium, ⁵Division of Rheumatology Allergy and Immunology, University of California San Diego, San Diego, CA
Background/Purpose: Axial spondyloarthritis (axSpA) includes both ankylosing spondylitis (AS, meeting modified New York criteria) and axSpA with no sacroiliitis on X-ray (non-radiographic axSpA, nr-axSpA). AS…
Abstract Number: 1413 • 2013 ACR/ARHP Annual Meeting
Long-Term Safety and Efficacy Of Certolizumab Pegol In Combination With Methotrexate In The Treatment Of Rheumatoid Arthritis: 5-Year Results From a 52-Week Randomized Controlled Trial and Open-Label Extension Study
Edward Keystone¹, Robert Landewé², Ronald van Vollenhoven³, Bernard Combe⁴, Vibeke Strand⁵, Philip J. Mease⁶, Laura Shaughnessy⁷, Brenda VanLunen⁷ and Désirée van der Heijde⁸, ¹University of Toronto, Toronto, ON, Canada, ²Academic Medical Center Amsterdam & Atrium Medical Center, Heerlen, Netherlands, ³Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ⁴Montpellier University Hospital, Montpellier, France, ⁵Adjunct, Division of Immunology / Rheumatology, Stanford University, Palo Alto, CA, ⁶Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ⁷UCB Pharma, Raleigh, NC, ⁸Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: In the RAPID1 randomized controlled trial (RCT; NCT00152386),1 certolizumab pegol (CZP) every 2 weeks (Q2W) plus MTX over 52 weeks (wks) provided rapid improvements…
Abstract Number: 431 • 2013 ACR/ARHP Annual Meeting
Prediction Of Week 52 Treatment Response Based On A Week 12 Assessment In Rheumatoid Arthritis Patients Receiving Certolizumab Pegol: Comparison Of A Patient-Reported Instrument Versus Physician-Based Disease Activity Assessment
Jeffrey R. Curtis¹, Willem Koetse², Jeymi Tambiah³, Lucian Ionescu⁴ and Yusuf Yazici⁵, ¹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²UCB Pharma, Raleigh, NC, ³UCB Pharma, Smyrna, GA, ⁴UCB Pharma, Brussels, Belgium, ⁵New York University Hospital for Joint Diseases, New York, NY
Background/Purpose: Guidelines support early intervention in rheumatoid arthritis (RA).1,2 The aim was to prospectively test whether outcome assessment at 12 weeks (wks) using a patient-reported…
Abstract Number: 1705 • 2012 ACR/ARHP Annual Meeting
Effect of Certolizumab Pegol On Inflammation of Spine and Sacroiliac Joints in Patients with Axial Spondyloarthritis: 12 Week Magnetic Resonance Imaging results of a Phase 3 Double Blind Randomized Placebo-Controlled Study
Désirée van der Heijde¹, Walter P. Maksymowych², Robert B. M. Landewé³, Christian Stach⁴, Bengt Hoepken⁴, Andreas Fichtner⁴, Danuta Kielar⁵ and Jürgen Braun⁶, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Department of Medicine, University of Alberta, Edmonton, AB, Canada, ³Academic Medical Center/University of Amsterdam & Atrium Medical Center, Amsterdam, Netherlands, ⁴UCB Pharma, Monheim am Rheim, Germany, ⁵UCB Pharma, Brussels, Belgium, ⁶Rheumazentrum Ruhrgebiet, Herne, Germany
Background/Purpose: Axial spondyloarthritis (axSpA) includes both ankylosing spondylitis (AS) and non-radiographic axSpA (nr-axSpA) and is defined by the ASAS criteria.1 It is characterized by bone…
Abstract Number: 1643 • 2012 ACR/ARHP Annual Meeting
Outcomes of Pregnancy in Subjects Exposed to Certolizumab Pegol
Megan E. B. Clowse¹, Douglas C. Wolf², Christian Stach³, Gordana Kosutic⁴, Susan Williams⁴, Ido Terpstra⁵ and Uma Mahadevan⁶, ¹Rheumatology, Duke University Medical Center, Durham, NC, ²Atlanta Gastroenterology Associates, Atlanta, GA, ³UCB Pharma, Monheim, Germany, ⁴UCB Pharma, Raleigh, NC, ⁵UCB Pharma, Brussels, Belgium, ⁶University of California, San Francisco, San Francisco, CA
Background/Purpose: Certolizumab pegol (CZP) is an Fc-free, PEGylated, anti-TNF approved in the US for the treatment of Crohn's disease (CD) and rheumatoid arthritis (RA). Pre-clinical…
Abstract Number: 557 • 2012 ACR/ARHP Annual Meeting
Effect of Certolizumab Pegol On the Multiple Facets of Psoriatic Arthritis As Reported by Patients: 24 Week Patient Reported Outcome Results of a Phase 3 Double Blind Randomized Placebo-Controlled Study
Dafna D. Gladman¹, Roy Fleischmann², Geoffroy Coteur³, Franz Woltering⁴ and Philip J. Mease⁵, ¹Centre for Prognosis Studies in The Rheumatic Diseases, Toronto Western Research Institute, University of Toronto, University Health Network, Toronto, ON, Canada, ²University of Texas Southwestern Medical Center at Dallas, Dallas, TX, ³UCB Pharma, Brussels, Belgium, ⁴UCB Pharma, Monheim, Germany, ⁵Seattle Rheumatology Associates, Seattle, WA
Background/Purpose: RAPID-PsA (NCT01087788) reports efficacy and safety of certolizumab pegol (CZP), a PEGylated Fc-free anti-TNF, in psoriatic arthritis (PsA).1 The effect of different imputation methodologies…
Abstract Number: 558 • 2012 ACR/ARHP Annual Meeting
Rapid Improvements in Patient Reported Outcomes with Certolizumab Pegol in Patients with Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis: 24 Week Results of a Phase 3 Double Blind Randomized Placebo-Controlled Study
Joachim Sieper¹, Alan J. Kivitz², A.M. Van Tubergen³, Atul A. Deodhar⁴, Geoffroy Coteur⁵, Franz Woltering⁶ and Robert B. M. Landewé⁷, ¹Medical Department I, Rheumatology, Charité University Medicine, Berlin, Germany, ²Altoona Center for Clinical Research, Duncansville, PA, ³Department of Medicine, Maastricht University Medical Center, Maastricht, Netherlands, ⁴Oregon Health & Science University, Portland, OR, ⁵UCB Pharma, Brussels, Belgium, ⁶UCB Pharma, Monheim, Germany, ⁷Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands
Background/Purpose: Axial spondyloarthritis (axSpA) is a form of spondyloarthritis (SpA) that includes both ankylosing spondylitis (AS) and non-radiographic axial SpA (nr-axSpA), as defined by the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].